Many life science organizations collect sensitive data through outdated web forms, exposing companies to critical vulnerabilities, data breaches, regulatory penalties, and more.
- Here's What You Need To Know About The Access Consortium Pathway
- FDA Draft Guidance On CES Signals More Reliance On Toxicity And PK
- Maximizing The Value Of An Internal Audit Program In Pharmaceutical Quality Operations
- AI Is Not The CMC Revolution You're Looking For, And That's OK
- Phages As A Pharmaceutical: New EMA Guidance On Antimicrobial Drug Development
- How To Improve Sponsor–CMO Collaboration Around Digital Deviations
- Solving The Stem Cell Consistency Conundrum With iMSCs
EDITOR'S DESK
-
AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing
At BioProcess International 2025, leaders from AbbVie and Amgen gave keynote presentations about how their companies are advancing product development through digital tools.
AI consultant Kat Kozyrytska advocates for ethical AI adoption and explains its potential to foster collaboration across the industry.
Takeda head of process development, Amy Shaw, explains what factors to consider when scaling up or scaling out cell therapy manufacturing.
DeciBio partner Carl Schoellhammer, Ph.D., speaks on the record with Bioprocess Online's chief editor Tyler Menichiello at the 2025 BioProcess International conference in Boston.
Nobel laureate, David Baltimore passed away at 87 years old, on September 6, 2025. He was widely regarded as a scientific visionary who at just 37, co-discovered reverse transcriptase, an enzyme that flipped molecular biology on its head by showing that genetic information could flow from RNA back to DNA, not just the other way around.
GUEST COLUMNISTS
-
Here's What You Need To Know About The Access Consortium Pathway
Five nations are collaborating on a work-sharing program to reduce regulatory duplication in drug development.
-
FDA Draft Guidance On CES Signals More Reliance On Toxicity And PK
The technology to measure alternative metrics is vastly improved. Now, FDA joins other regulators in deprioritizing comparative efficacy studies for biosimilars.
-
Maximizing The Value Of An Internal Audit Program In Pharmaceutical Quality Operations
A shrinking FDA and rising supply pressures demand stronger risk management and smarter internal audits. Here’s how pharma can truly “see things as they really are.”
-
AI Is Not The CMC Revolution You're Looking For, And That's OK
Advanced therapy development today is less about big funding, more about frugality. Artificial intelligence unlocks a competitive advantage.
-
Phages As A Pharmaceutical: New EMA Guidance On Antimicrobial Drug Development
The EMA has now issued a draft guidance on quality aspects of phage therapy medicinal products. Rising antimicrobial resistance has renewed interest in bacteriophages to fight pathogens.
-
How To Improve Sponsor–CMO Collaboration Around Digital Deviations
Digital strategies and standardized data models cut manual work, boost accuracy and speed of information sharing, and build trust between sponsors and CMOs.
-
Solving The Stem Cell Consistency Conundrum With iMSCs
The ability to produce unlimited batches of induced mesenchymal stem cells from a single iPSC cell bank is, perhaps, one of their most alluring features.
-
Sensitive Critical Starting Materials Need A 'Just-In-Data' Approach
Here's a blueprint for transforming the fragmented, high-risk interface between vector and cell therapy platforms into a unified, predictable, and compliant system.
BIOPROCESSING WHITE PAPERS
-
Biomanufacturing Readiness: A Validation Model For Multiproduct Facilities
Optimize your validation strategy to meet evolving regulatory demands and product complexities with a scalable, efficient framework that accelerates facility readiness and ensures consistent quality.
-
Upscaling hMSC Production Enhances EV Secretion And Cargo Profile12/19/2024
Explore how the dynamic microenvironment of bioreactors influences the production of extracellular vesicles (EVs), including exosomes, secreted by human mesenchymal stromal cells (hMSCs).
-
Improving Safety And Efficacy With Charged Variant Characterization5/14/2024
Discover how a CDMO with extensive experience in protein variant characterization, CQA analytics, and patient-centric product development can ensure the safety and efficacy of your biotherapeutic.
-
Combining Digital Platforms And QbD Principles7/9/2024
How can data and digitalization further improve pharmaceutical development and the continuous, quick, and efficient delivery of products?
-
Modular Automation: The Plug-And-Produce Opportunity For Life Sciences2/12/2025
Explore how the advantages of modular automation in life sciences emphasize flexibility, efficiency, and cost savings through plug-and-produce systems that enhance production adaptability and speed.
-
Factors Influencing CD34+ Cell Collection Efficiency In Leukapheresis6/3/2025
Efficiently collecting sufficient peripheral blood stem cells is paramount for successful transplantation, necessitating a deeper understanding of influencing factors and procedural nuances.
BIOPROCESSING APP NOTES & CASE STUDIES
- A Universal Solution For Ultra Cold Storage
- Simpler, Faster, Cheaper Advanced Therapy Manufacturing
- Rapid, Automated, At-Line Adenovirus Quantitation
- Leveraging Innovative Analytics To Ensure The Thermal Stability Of mAb Drug Products
- Optimizing End-To-End Processes To Reduce Costs And Improve Yields
- FDA Releases Draft Guidance To Accelerate Biosimilar Development
- Supporting The Next Generation Of ADCs
- AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing
- On The Ground At BPI: Kat Kozyrytska On Ethical AI And Collaboration
- On The Ground At BPI: Takeda's Amy Shaw On Scaling Cell Therapy Manufacturing
- On The Ground At BPI: Industry Reflections With Carl Schoellhammer, Ph.D.
- Single-Use Standardization Starts At Home
BIOPROCESS ONLINE CONTENT COLLECTIONS
This collection of articles digs into the industry’s growing focus on knowledge management as an indispensable facet of biomanufacturing and pharmaceutical development, exploring how it plays into risk management, quality, vendor relationships, and supply chain resilience.
More Content CollectionsFEATURED PRODUCTS AND SERVICES
ON-DEMAND WEBINARS
- Streamlining pDNA: Capacity, Complexity, And Cutting-Edge Solutions
- Are You Keeping Pace With Oligo Synthesis Optimization?
- From Readiness To Results: Unlocking Capacity For Expanding Product Demand
- Accelerating Early Phase Biologics From The Clinic To Commercialization
- Accelerate Your pDNA And mRNA Process Development
INDUSTRY NEWS
NEWSLETTER ARCHIVE
- 11.21.25 -- STREAM Edition: Developing Analytical Methods For Advanced ADCs
- 11.21.25 -- It's Not Just You, Everyone's Talking About OPV
- 11.20.25 -- Manufacturing Breakthroughs: γδ T Cells, CAR-T Automation, T Cell Expansion Solutions
- 11.20.25 -- Your trusted filters made closer to you – try by yourself!
- 11.20.25 -- Making The Right Choice: CMO Or CDMO?